Patents Examined by Quanglong N Truong
-
Patent number: 12023342Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.Type: GrantFiled: July 19, 2021Date of Patent: July 2, 2024Assignee: Avalyn Pharma Inc.Inventor: Mark William Surber
-
Patent number: 12023394Abstract: Methods and compositions for rapid and efficient assembly of substrates (e.g., fibers) coated with lamellar vesicles are provided, wherein the vesicles are more strongly attached to the substrate than those made using other methods.Type: GrantFiled: May 4, 2021Date of Patent: July 2, 2024Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Anand Bala Subramaniam
-
Patent number: 12016830Abstract: The present invention provides a high-dose oral pharmaceutical composition and high drug loading of isotretinoin with low fill-weight, and smaller size capsules, and methods of preparation and use thereof.Type: GrantFiled: June 27, 2023Date of Patent: June 25, 2024Assignee: Acrotech Biopharma, LLCInventors: Ashish Anvekar, Nagaprasad Vishnubhotla, Arun Jana
-
Patent number: 12016972Abstract: The apparatuses and methods described herein relates generally to the field of active agent (drug) release from surgical grafts useful for soft tissue reconstruction, regeneration, or repair. More particularly, described herein are surgical grafts for soft tissue repair that include an active agent that is released over time while advantageously matching the biomechanical properties of tissue during healing and recovery.Type: GrantFiled: January 20, 2023Date of Patent: June 25, 2024Assignee: TELA Bio, Inc.Inventor: E. Skott Greenhalgh
-
Patent number: 12011504Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an API, a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.Type: GrantFiled: March 21, 2023Date of Patent: June 18, 2024Assignee: Marenda Pharmaceuticals LLCInventors: Andrew Favara, Marc Karetny
-
Patent number: 12004630Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.Type: GrantFiled: February 8, 2022Date of Patent: June 11, 2024Assignee: L'OREALInventors: Henri Samain, Franck Giron, Guillaume Kergosien
-
Patent number: 12005035Abstract: Described herein is a composition that includes an N-methyl-D-aspartate receptor (NMDAR) antagonist and a TAS2R receptor response mediating agent for treating neuropathic pain and depression. Methods for treating chronic pain with the described composition are also described.Type: GrantFiled: August 14, 2023Date of Patent: June 11, 2024Inventor: Daniel C. Javitt
-
Patent number: 12005146Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.Type: GrantFiled: March 24, 2023Date of Patent: June 11, 2024Assignee: THERASYN SENSORS, INC.Inventors: Jerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
-
Patent number: 12005141Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.Type: GrantFiled: June 22, 2023Date of Patent: June 11, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Jayanta Kumar Mandal, Malay Patel, Swati Nagar, Michael Paul DeHart
-
Patent number: 11998104Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.Type: GrantFiled: February 8, 2022Date of Patent: June 4, 2024Assignee: L'OREALInventors: Henri Samain, Franck Giron, Guillaume Kergosien
-
Patent number: 11998634Abstract: The invention relates to new emulsion formulations comprising polyethylene glycol (15)-hydroxystearate, polyglyceryl-3 oleate and one, two, three or more anti-cancer drugs as well as such emulsion formulations for use in the treatment of cancer and a method for producing such emulsion formulations. Preferably, the emulsion formulation can further comprise one or more immunomodulatory drugs or adjuvant.Type: GrantFiled: December 6, 2019Date of Patent: June 4, 2024Assignee: CAPNOPHARM GMBHInventor: Ranjita Sahoo
-
Patent number: 11998555Abstract: Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.Type: GrantFiled: January 30, 2020Date of Patent: June 4, 2024Assignee: scPharmaceuticals Inc.Inventors: Alfredo Grossi, Britt Kostraba, Olatokumbo O. Luca Ogunleye, Shannon Terry, Franciscus Koppenhagen
-
Patent number: 11980277Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.Type: GrantFiled: February 8, 2022Date of Patent: May 14, 2024Assignee: L'OREALInventors: Henri Samain, Franck Giron, Guillaume Kergosien
-
Patent number: 11980685Abstract: Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain an amount of a tafamidis of from 0.5 mg/ml to 20 mg/ml, water, and an amount of an alkaline pH modifier that yields a content of the tafamidis solubilized in the water of from 0.5 mg/ml to 19.8 mg/ml.Type: GrantFiled: December 23, 2022Date of Patent: May 14, 2024Assignee: TaP Pharmaceuticals, AGInventors: Nilesh Parikh, William Hite
-
Patent number: 11974651Abstract: The invention relates to a system (10) for dispensing a product, comprising a dispenser that can house at least two cartridges, each of which includes a reservoir containing a base product, a first base product comprising at least 0.1 wt.-% particles having a density differential relative to the medium containing same, preferably of at least 0.5 g/cm3, in particular particles having a density greater than or equal to 2 g/cm3, and a thickening agent. The dispenser allows at least two base products to be dispensed in adjustable proportions, the viscosity of the first base product being preferably greater than 2 Pa·s and more preferably greater than or equal to 4 Pa·s.Type: GrantFiled: February 8, 2022Date of Patent: May 7, 2024Assignee: L'OREALInventors: Henri Samain, Franck Giron, Guillaume Kergosien
-
Patent number: 11975021Abstract: Compositions for treating inflammatory skin conditions are described. The compositions can include povidone iodine in aqueous solution, hydrocortisone, diphenhydramine, an emulsifier, and a hydrophobic carrier, where the povidone iodine aqueous solution is emulsified in the hydrophobic carrier. A method of preparing a composition is also described. The method can include adding an aqueous solution of povidone iodine to a hydrophobic carrier, and adding an emulsifier to the hydrophobic carrier at a concentration that emulsifies the aqueous solution of povidone iodine in the hydrophobic carrier upon mixing.Type: GrantFiled: October 9, 2023Date of Patent: May 7, 2024Inventor: James Kojian
-
Patent number: 11975099Abstract: The present invention relates to an ethanol foam sclerosing agent for vascular anomalies and a preparation method thereof. The ethanol foam sclerosing agent includes absolute ethanol, water, Tween 80 and a stabilizer. The ethanol foam sclerosing agent further includes hyaluronic acid. The mass composition of the ethanol foam sclerosing agent includes 32-42% of absolute ethanol, 0.5-2% of Tween 80, 0-25% (excluding 0) of egg yolk lecithin, 0-2% (excluding 0) of hyaluronic acid, and the balance of water. The stabilizer is hyaluronic acid or glycerin. Foam is prepared by the Tessari method. While the original therapeutic effect of ethanol is not changed, the side effect of the ethanol is significantly reduced.Type: GrantFiled: December 11, 2019Date of Patent: May 7, 2024Assignee: QILU HOSPITAL OF SHANDONG UNIVERSITYInventors: Shaohua Liu, Hanshu Zhang, Aijun Yang, Yiran Liu
-
Patent number: 11969426Abstract: The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.Type: GrantFiled: April 19, 2022Date of Patent: April 30, 2024Assignee: Genentech, Inc.Inventors: Reinhard Reents, Pirmin Hidber, Andre Hell, Peter Steidle, Martin Wunderlich, Marie Pepelnjak, Francis Gosselin, Edward Yost
-
Patent number: 11957647Abstract: Disclosed is a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of: (a) a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; and (b) a pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15. Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate.Type: GrantFiled: May 24, 2023Date of Patent: April 16, 2024Assignee: OREXO ABInventors: Jonas Sävmarker, Robert Rönn
-
Patent number: 11957644Abstract: A therapeutic composition and a method of producing it by light-activating hypericin in a carrier or solvent. Preferably, the composition is made by combining dried flowers and/or flower stems of St. John's Wort with edible oil and exposing the mixture to the sun for a prolonged time. This process serves to light-activate the hypericin before its use and reduce risk of skin phototoxicity. The composition can be used for treating undesirable conditions such as mouth sores and vaginal infections.Type: GrantFiled: October 5, 2022Date of Patent: April 16, 2024Inventors: Natasa Stojanovic, Robert D. Fish